Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBT Margin (2020 - 2025)

Journey Medical (DERM) has disclosed EBT Margin for 6 consecutive years, with 13.6% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin rose 274.0% year-over-year to 13.6%, compared with a TTM value of 14.53% through Sep 2025, up 3308.0%, and an annual FY2024 reading of 26.03%, down 1994.0% over the prior year.
  • EBT Margin was 13.6% for Q3 2025 at Journey Medical, up from 24.89% in the prior quarter.
  • Across five years, EBT Margin topped out at 48.88% in Q3 2023 and bottomed at 99.99% in Q2 2021.
  • Average EBT Margin over 5 years is 33.37%, with a median of 31.0% recorded in 2025.
  • Peak annual rise in EBT Margin hit 11409bps in 2023, while the deepest fall reached -7752bps in 2023.
  • Year by year, EBT Margin stood at 76.59% in 2021, then increased by 13bps to 66.76% in 2022, then surged by 171bps to 47.33% in 2023, then crashed by -75bps to 11.62% in 2024, then crashed by -217bps to 13.6% in 2025.
  • Business Quant data shows EBT Margin for DERM at 13.6% in Q3 2025, 24.89% in Q2 2025, and 31.0% in Q1 2025.